HMGB1 in Hormone-Related Cancer: a Potential Therapeutic Target

被引：27

作者：

Srinivasan, Madhuwanti ^{[1
]}

Banerjee, Souresh ^{[1
]}

Palmer, Allison ^{[1
]}

Zheng, Guoxing ^{[1
]}

Chen, Aoshuang ^{[1
]}

Bosland, Maarten C. ^{[2
]}

Kajdacsy-Balla, Andr ^{[2
]}

Kalyanasundaram, Ramaswamy ^{[1
]}

Munirathinam, Gnanasekar ^{[1
,3
]}

机构：

[1] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA

[2] Univ Illinois, Dept Pathol, Chicago, IL USA

[3] Univ Illinois, Ctr Canc, Chicago, IL USA

来源：

HORMONES & CANCER | 2014年 / 5卷 / 03期

关键词：

MOBILITY GROUP BOX-1; END-PRODUCTS RAGE; DNA-BINDING; CELL-DEATH; PROGESTERONE-RECEPTOR; CHROMATIN PROTEINS; MESSENGER-RNA; LETHAL SEPSIS; CALF-THYMUS; BETA-CELLS;

D O I：

10.1007/s12672-014-0175-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-mobility group box 1 (HMGB1) is a dynamic nuclear protein participating in transcription, chromatin remodelling, and DNA recombination and repair processes. Accumulating evidence indicates that its function now extends beyond the nucleus, notably its extracellular role in inflammation. HMGB1 is implicated as a late mediator of sepsis and is also believed to promote atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, deregulation of HMGB1 is shown to be associated with the hallmarks of cancer development. Moreover, several clinical studies have shown that HMGB1 is a promising biomarker for a variety of cancer types. In this review, we provide novel insights into the role and mechanisms of HMGB1, in particular, to hormone-related cancers and its potential to serve as a therapeutic target.

引用

页码：127 / 139

页数：13

共 50 条

[31] HMGB1 as a late mediator and therapeutic target in sepsis.
Yang, H
Czura, CJ
Tracey, KJ
SHOCK, 2005, 23 : 29 - 29
[32] HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell
Ugrinova, I.
Pasheva, E.
CHROMATIN PROTEINS AND TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS, 2017, 107 : 37 - 76
[33] HMGB1 is a promising therapeutic target for acute liver failure
Yamamoto, Tetsu
Tajima, Yoshitsugu
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (07) : 673 - 682
[34] HMGB1 as a therapeutic target for sepsis: it's all in the timing!
Gentile, Lori F.
Moldawer, Lyle L.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (03) : 243 - 245
[35] High Mobility Group Box Protein (HMGB1): A Potential Therapeutic Target for Diabetic Encephalopathy
Dash, Udit Kumar
Mazumdar, Debashree
Singh, Santosh
MOLECULAR NEUROBIOLOGY, 2024, 61 (10) : 8188 - 8205
[36] HMGB1: A potential target for treatment of benign prostatic hyperplasia
Xue Rui
Ma Shengli
Jia Zhankui
Pi Guofu
Yang Jinjian
MEDICAL HYPOTHESES, 2013, 81 (05) : 892 - 895
[37] HMGB1: A Possible Crucial Therapeutic Target for COVID-19?
Street, Maria Elisabeth
HORMONE RESEARCH IN PAEDIATRICS, 2020, 93 (02): : 73 - 75
[38] Interaction between HMGB1/Tetranectine as a possible therapeutic target in sepsis?
Adimi, Yasmine
Esposito, Mathieu
Braik, Rayan
Pol, Jonathan
M S-MEDECINE SCIENCES, 2021, 37 (8-9): : 820 - 822
[39] HMGB1 expression in sickle cell disease: A pro-inflammatory cytokine and potential therapeutic target
Barginear, Myra F.
Chandok, Anu G.
Sison, Cristina
Yang, Lihong
Budman, Daniel R.
D'Olimpio, James
Tracey, Kevin J.
Bradley, Thonnas
BLOOD, 2007, 110 (11) : 18B - 18B
[40] Roles and therapeutic application of extracellular HMGB1 in gastric cancer
Konishi, Hirotaka
Arita, Tomohiro
Nishibeppu, Keiji
Ohashi, Takuma
Shimizu, Hiroki
Yamamoto, Yusuke
Shiozaki, Atsushi
Kubota, Takeshi
Fujiwara, Hitoshi
Otsuji, Eigo
CANCER SCIENCE, 2024, 115 : 265 - 265

← 1 2 3 4 5 →